TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 849710

Group type: EXPERIMENTAL
Intervention: Patients with pericarditis
Number of subjects: 909

Group type: COMPARATOR
Intervention: Patients without pericarditis
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment
Number of subjects: 909
Study: 31514564

Group type: EXPERIMENTAL
Intervention: Mirror therapy combined with power and strength exercises
Number of subjects: 30
Study: 30847640

Group type: EXPERIMENTAL
Intervention: Cit + Arg
Number of subjects: 24
Study: 28437147

Group type: EXPERIMENTAL
Intervention: Meditation with a coach
Number of subjects: 28

Group type: COMPARATOR
Intervention: Self-meditation with a CD
Number of subjects: 28
Study: 26029985

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months for 36 months
Number of subjects: 7808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 7808
Study: 24330810

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for chronic dizziness
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham acupuncture treatment for chronic dizziness
Number of subjects: 80
Study: 21670727

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol + dydrogesteron (37.5 µg/24h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol + medroxyprogesteron (50 µg/24h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral estradiol + noretisteron (1mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study: 19424460

Group type: EXPERIMENTAL
Intervention: Health extension workers (HEWs) trained to identify TB suspects, collect sputum, and provide directly observed treatment in intervention kebeles.
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group without HEWs involvement.
Number of subjects: 318
Study: 16771791

Group type: EXPERIMENTAL
Intervention: Bicalutamide 300 mg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Bicalutamide 450 mg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Bicalutamide 600 mg
Number of subjects: 248

Group type: COMPARATOR
Intervention: Castration
Number of subjects: 248
Study: 15024300

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5, 10, 20, 40, or 80 mg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5-80 mg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (doses > 5 mg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 11122839

Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy regimens with radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy regimens without radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic score for advanced-stage Hodgkin's disease
Number of subjects: 0
Study: 9262937

Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard medication clinic approach
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standardized pharmacotherapeutic protocol
Number of subjects: 42
Study: 7967433

Group type: EXPERIMENTAL
Intervention: COALL therapy-protocol
Number of subjects: 286
Study: 3483368

Group type: EXPERIMENTAL
Intervention: 1 filled chocolate product (FCP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 filled chocolate products (FCP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0 filled chocolate products (FCP)
Number of subjects: 18
Study: 30332319

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) with four sets of four repetitions at 90% 1RM
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Eccentric maximal strength training (eMST) with an augmented eccentric load of 150% 1RM
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 53
Study: 27363489

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25031312

Group type: EXPERIMENTAL
Intervention: QuitTxt (text messaging intervention)
Number of subjects: 862
Study: 22889406

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Low-glycemic-load diet
Number of subjects: 181
Study: 20553948

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 91

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 91
Study: 18726159

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychotropic medications
Number of subjects: 0
Study: 16431378

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg tablets (fasted state)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg tablets (fed state)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg tablets
Number of subjects: 4
Study: 12860856

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 30 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10937118

Group type: EXPERIMENTAL
Intervention: Octyl-2-cyanoacrylate (Dermabond; Ethicon Inc, Somerville, NJ) tissue glue
Number of subjects: 20

Group type: COMPARATOR
Intervention: 6.0 suture (polypropylene or fast-absorbing gut)
Number of subjects: 20
Study: 8872133

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering drug (simvastatin)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Subjects with TC > 249 mg/dl
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: F1 + 2 plasma levels
Number of subjects: 68
Study: 1518317

Group type: EXPERIMENTAL
Intervention: Home BP group
Number of subjects: 215

Group type: COMPARATOR
Intervention: Usual Care (UC) group
Number of subjects: 215
Study: 6638413

Group type: EXPERIMENTAL
Intervention: Rush treatment schedule
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Conventional treatment schedule
Number of subjects: 42

Group type: COMPARATOR
Intervention: HBV treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: YJV treatment
Number of subjects: 42
Study: 30227904

Group type: EXPERIMENTAL
Intervention: GC-FID method for determining ethanol in kombucha
Number of subjects: 8
Study: 29150198

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Sublingual buprenorphine-naloxone (BUP-NX)
Number of subjects: 570
Study: 26529239

Group type: EXPERIMENTAL
Intervention: Awareness material about a person coping with suicidal ideation by getting professional help (low social similarity)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Awareness material about a person coping with suicidal ideation by getting professional help (high social similarity)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group reading an article unrelated to suicide
Number of subjects: 112
Study: 24886683

Group type: EXPERIMENTAL
Intervention: Interpersonal problem-solving therapy plus treatment-as-usual
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment-as-usual alone
Number of subjects: 60
Study: 22784777

Group type: EXPERIMENTAL
Intervention: Tanezumab (2.5, 5, or 10 mg)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 690

Group type: COMPARATOR
Intervention: Tanezumab and Placebo
Number of subjects: 690
Study: 18855928

Group type: EXPERIMENTAL
Intervention: 16-item odor identification test
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combination of 16-item identification test and detection threshold task
Number of subjects: 102
Study: 17450372

Group type: EXPERIMENTAL
Intervention: Non-bicarbonate buffers (beta(nbi)) during exercise
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Non-bicarbonate buffers (beta(nbi)) during recovery
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bicarbonate buffering (beta(bi)) during and after exercise
Number of subjects: 34
Study: 15241158

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite and tricalcium phosphate coating
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control (no coating)
Number of subjects: 318
Study: 11409308

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (ventriculoscopic operation)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (VP shunting)
Number of subjects: 88
Study: 9777179

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 423
Study: 7935654

Group type: EXPERIMENTAL
Intervention: Zidovudine regimen (100 mg orally five times daily antepartum, 2 mg/kg intravenously during labor, 1 mg/kg/hour until delivery, and 2 mg/kg orally every six hours for six weeks for newborns)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 477
Study: 3067924

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 300 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flurbiprofen b.i.d. (twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flurbiprofen t.i.d. (thrice daily)
Number of subjects: 40
Study: 30227841

Group type: EXPERIMENTAL
Intervention: Culturally enhanced pain coping skills training (CST) program
Number of subjects: 0
Study: 26278222

Group type: EXPERIMENTAL
Intervention: Self-management support service (depression self-management training, recovery coaching, care coordination)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 302
Study: 24350662

Group type: EXPERIMENTAL
Intervention: Oxybutynin patch
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Propiverine
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1530
Study: 22500659

Group type: EXPERIMENTAL
Intervention: Yoga program (specific asanas, pranayamas, meditation, yogic counselling, lectures on yoga philosophy)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physical therapy exercises (control group)
Number of subjects: 80
Study: 19500939

Group type: EXPERIMENTAL
Intervention: Standard CPR
Number of subjects: 106

Group type: COMPARATOR
Intervention: Over-the-head CPR
Number of subjects: 106
Study: 18269639

Group type: EXPERIMENTAL
Intervention: Metformin (M group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glyburide (G group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C group)
Number of subjects: 30
Study: 16003735

Group type: EXPERIMENTAL
Intervention: VIA
Number of subjects: 131178

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 131178

Group type: EXPERIMENTAL
Intervention: HPV
Number of subjects: 131178
Study: 12942563

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg as a 15-minute infusion)
Number of subjects: 74
Study: 10632128

Group type: EXPERIMENTAL
Intervention: G-suit inflation with LBNP (50 mm Hg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (baseline without G-suit and LBNP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: LBNP (50 mm Hg)
Number of subjects: 12
Study: 8867251

Group type: EXPERIMENTAL
Intervention: 100 mg Ro 15‐8081 (divided into 2 doses)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg/day, piroxicam in the morning and placebo in the evening)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 522
Study: 1325728

Group type: EXPERIMENTAL
Intervention: Uridine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6334234

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Portacaval shunt
Number of subjects: 52
Study: 31119758

Group type: EXPERIMENTAL
Intervention: Simulated fight response against an angry opponent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated fight with aversive white noise after losing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aversive noise after losing to an angry opponent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replication of aversive noise after losing to an angry opponent
Number of subjects: 0
Study: 28832393

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg body mass)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 27605955

Group type: EXPERIMENTAL
Intervention: Prophylactic phenylephrine weight adjusted dose infusion at 0.5 micrograms per kilogram per minute
Number of subjects: 108

Group type: COMPARATOR
Intervention: Prophylactic phenylephrine fixed dose infusion at 37.5 micrograms per minute
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 25240737

Group type: EXPERIMENTAL
Intervention: Tips booklet intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control fact sheet
Number of subjects: 120
Study: 22157370

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 19544555

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normal participants, age and sex matched)
Number of subjects: 40
Study: 17414226

Group type: EXPERIMENTAL
Intervention: Duloxetine 200 mg twice daily
Number of subjects: 117

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 15746789

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Harmonic Scalpel (HS) and Electrocautery
Number of subjects: 60
Study: 12538373

Group type: EXPERIMENTAL
Intervention: Lidocaine-epinephrine-bicarbonate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lidocaine-epinephrine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 27
Study: 10759934

Group type: EXPERIMENTAL
Intervention: Pericranial injection of 10 x 20 mouse units botulinum toxin A
Number of subjects: 21

Group type: COMPARATOR
Intervention: Injection of isotonic saline (placebo)
Number of subjects: 21
Study: 8785134

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study: 1993808

Group type: EXPERIMENTAL
Intervention: Budesonide (reduced dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Budesonide (maintained dose)
Number of subjects: 28
Study: 6467838

Group type: EXPERIMENTAL
Intervention: Resting plasma noradrenaline levels in females
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Resting plasma adrenaline levels in males
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Plasma noradrenaline concentration after isometric exercise, mental arithmetic and cold pressor testing
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Resting noradrenaline concentration in males
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Resting noradrenaline concentration in females
Number of subjects: 90
Study: 29359339

Group type: EXPERIMENTAL
Intervention: Subcrestal implants (adapted to soft tissue thickness)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Equicrestal implants (control)
Number of subjects: 25
Study: 28893309

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone/naloxone (OXN-CR)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Controlled-release oxycodone (OX-CR)
Number of subjects: 128
Study: 25339501

Group type: EXPERIMENTAL
Intervention: Intradiscal biacuplasty (IDB) treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cross-over from sham to IDB treatment
Number of subjects: 57
Study: 24184428

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Minimal Attention (MA)
Number of subjects: 171
Study: 21388602

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBT-D)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Relaxation training control (RTC)
Number of subjects: 165
Study: 18208600

Group type: EXPERIMENTAL
Intervention: Active test product (Hyal-Joint) 80 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16364496

Group type: EXPERIMENTAL
Intervention: Mycoprotein preload
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tofu preload
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chicken preload
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mycoprotein and Tofu preloads
Number of subjects: 42
Study: 12760974

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 15

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia
Number of subjects: 15
Study: 10883868

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 29
Study: 9228104

Group type: EXPERIMENTAL
Intervention: High-field MR system (1.5 T)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-field MR system (0.2 T)
Number of subjects: 20
Study: 1580284

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg once daily
Number of subjects: 190

Group type: COMPARATOR
Intervention: Atenolol 25 mg once daily
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 190

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 190
Study: 6367326

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 157

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 157
Study: 30920122

Group type: EXPERIMENTAL
Intervention: Sorafenib 800 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorafenib 600 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated dose-reduction strategy of Sorafenib 800 mg/day for initial two cycles followed by dose reductions
Number of subjects: 0
Study: 29340321

Group type: EXPERIMENTAL
Intervention: Abatacept (modified CTLA4‐Ig) administered for 4 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study: 27696017

Group type: EXPERIMENTAL
Intervention: Laser irradiation at 780 nm, 40 mW, 4 J/cm2 (G3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser irradiation at 780 nm, 40 mW, 40 J/cm2 (G4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laser placebo-sham irradiation (G2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 60
Study: 24127838

Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation (PVS) device (FERTI CARE(®) vibrator), used daily for at least 1 week before surgery and for 6 weeks after catheter removal.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no PVS intervention).
Number of subjects: 68
Study: 22103808

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) during isoflurane anesthesia (n = 20)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC) during propofol anesthesia (n = 14)
Number of subjects: 72
Study: 20202536

Group type: EXPERIMENTAL
Intervention: 1.0 g oral acetaminophen
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 17993955

Group type: EXPERIMENTAL
Intervention: Successfully nonoperatively managed splenic injuries (n=15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Splenectomies (n=14)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controls with normal splenic function (n=15)
Number of subjects: 40
Study: 15794175

Group type: EXPERIMENTAL
Intervention: Add-on melatonin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Add-on placebo
Number of subjects: 31
Study: 12473256

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (run-in)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 104
Study: 9796070

Group type: EXPERIMENTAL
Intervention: Ultra-high dosage streptokinase (1.5 million U/h for 6h daily, n = 77)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional dosage streptokinase (100,000 U/h, n = 79)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ultra-high dosage streptokinase (group A)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional dosage streptokinase (group B)
Number of subjects: 156
Study: 8582783

Group type: EXPERIMENTAL
Intervention: Zinc sulphate 200 mg orally for 30 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Zinc sulphate supplementation
Number of subjects: 29

Group type: COMPARATOR
Intervention: AZT only (control)
Number of subjects: 29
Study: 2653391

Group type: EXPERIMENTAL
Intervention: Flosequinan 100 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17427

Group type: EXPERIMENTAL
Intervention: Fazadinium 1 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fazadinium 0.5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancuronium 0.08 mg/kg
Number of subjects: 0
Study: 30701343

Group type: EXPERIMENTAL
Intervention: Osteoporosis Self Efficacy Scale (OSE)
Number of subjects: 7749
Study: 29070055

Group type: EXPERIMENTAL
Intervention: Arthroscopic internal drainage (Group A)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Open excision after arthroscopic treatment (Group B)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Open excision (Group C)
Number of subjects: 76
Study: 25349226

Group type: EXPERIMENTAL
Intervention: ECVUE™
Number of subjects: 42

Group type: COMPARATOR
Intervention: 12-lead ECG algorithms
Number of subjects: 42